Focused On-demand Library for Potassium channel subfamily T member 2

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

PARTNER
Receptor.AI
 
UPACC
Q6UVM3

UPID:
KCNT2_HUMAN

ALTERNATIVE NAMES:
Sequence like an intermediate conductance potassium channel subunit; Sodium and chloride-activated ATP-sensitive potassium channel Slo2.1

ALTERNATIVE UPACC:
Q6UVM3; Q3SY59; Q5VTN1; Q6ZMT3

BACKGROUND:
The protein Potassium channel subfamily T member 2, with alternative names such as Sequence like an intermediate conductance potassium channel subunit and Sodium and chloride-activated ATP-sensitive potassium channel Slo2.1, is vital for producing rapidly activating outward rectifier K(+) currents. Its function is essential for the regulation of potassium ions across the cell membrane, influenced by intracellular sodium, chloride, and ATP levels.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Potassium channel subfamily T member 2 could open doors to potential therapeutic strategies. Its involvement in Developmental and Epileptic Encephalopathy 57 highlights its significance in neurological health and disease, presenting a promising target for drug discovery efforts aimed at treating epileptic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.